Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes
- PMID: 18840741
- PMCID: PMC3638903
Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes
Abstract
Although type 2 diabetes (DM) is a recognized risk factor for development of tuberculosis (TB), the impact on treatment is unclear. Among the few published reports, some suggest that mycobacterial clearance during treatment is delayed in TB patients with DM. Using survival analysis on data from 469 culture-positive TB patients retrospectively identified in south Texas, we found DM to be an independent risk factor for a 5-day delay in mycobacterial clearance within the first 60 days of treatment.
Figures
References
-
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. - PubMed
-
- Oscarsson N, Silwer H. Incidence of pulmonary tuberculosis among diabetics. Acta Med Scand. 1958;160(suppl 335):23–48. - PubMed
-
- Ponce-De-Leon A, Garcia-Garcia Md ML, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Olaiz-Fernandez G, Rogas R, Ferreyra-Reyes L, Cano-Arellano B, Bobadilla M, Small PM, Sifuentes-Osornia J. Tuberculosis and diabetes in southern Mexico. Diabetes Care. 2004;27:1584–1590. - PubMed
-
- Alisjahbana B, van CR, Sahiratmadja E, den HM, Maya A, Istriana E, Danusantoso H, Ottenhoff TH, Nelwan RH, van der Meer JW. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis. 2006;10:696–700. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical